Allegheny Health Network (AHN) Cancer Institute has become the first health care system in Western Pennsylvania to offer a first-of-its-kind cellular therapy recently approved by the U.S. Food and Drug Administration to treatmetastaticmelanoma.
Amtagvi provides new hope for adult patients with hard-to-treat melanoma. This includes patients who haven't had success with other medications, have skin cancer that can't be removed through surgery (unresectable), or have skin cancer that has spread throughout the body (metastatic).
The one-time treatment, made by Iovance Biotherapeutics, is the first FDA-approved T-cell therapy...
Login or create a forever free account to read this news
Sign up/Log in